Recognizing that SKP2 loss causes synthetic lethality in RB1 null cells, Aubry and colleagues explored the therapeutic potential of the SKP2 inhibitor MLN4924 in treating retinoblastoma [71]. This evidence concerns the gene RB1 and retinoblastoma.